MeVis Medical Solutions AG

Regulatory Filings • Nov 27, 2009

News Details

Corporate | 27 November 2009 09:00

With the launch of the latest multimodality software generation for industry partner Hologic, MeVis Medical Solutions sets a new benchmark in image-based breast cancer diagnostics

MeVis Medical Solutions AG / Product Launch

27.11.2009

Dissemination of a Corporate News, transmitted by
DGAP - a company of EquityStory AG.
The issuer / publisher is solely responsible for the content of this announcement.

---

Leading breast diagnostic software used on Hologic SecurView(R) DX
multimodality diagnostic workstations is now supporting innovative
cross-modality workflow

* First license sales of the new multimodality software generation
customized for use on Hologic SecurView(R) DX diagnostic workstations
* Innovative software technologies for all imaging modalities are combined
in a single diagnostic workstation software package
* User-defined clinical cross-modality workflows enhance multimodality
breast diagnostics

Bremen, November 27, 2009 - MeVis Medical Solutions AG [ISIN:
DE000A0LBFE4], a leading medical imaging software company with focus on
dedicated, disease-oriented clinical applications, today announced that the
new multimodality version of its breast diagnostics software have been
integrated into Hologic's latest software release for its SecurView(R)
diagnostic workstation.
Hologic, Inc., supplies the SecurView(R) DX, diagnostic workstations and
markets them globally. The new workstation software supports review of all
breast imaging modalities, including 3D tomosynthesis images generated on
the Hologic Selenia(R) DimensionsTM system, in concert with review of
digital mammograms. Hologic's Selenia(R) DimensionsTM Breast Tomosynthesis
system is available in Europe, Canada, and other countries and awaiting FDA
approval in the United States.

Breast cancer is the most common form of malignant tumor in the world
according to the American Cancer Society, which estimates that in 2007 a
total of more than 1.3 million women were diagnosed with breast cancer
worldwide. That corresponds to approximately 23 percent of new cases of
cancer in women, and to approximately 10.6 percent of all new cancer cases
in men and women combined.

In addition to the digital mammography used in screening programs, a range
of new imaging technologies have been developed for the specific purpose of
improving the diagnosis of breast cancer (mammary carcinomas). These
include contrast-enhanced MRI (magnetic resonance imaging), ultrasound,
and, most recently, the highly innovative digital tomosynthesis of the
breast. The spatial perspective of this imaging modality offers clear
advantages over two-dimensional digital mammography, which is used as
standard in breast cancer screening at present. These benefits become
particularly relevant in the case of dense breast tissue, where the spatial
perspective can help the doctor distinguish between overlapping tissue and
real suspicious densities. Moreover, the specific diagnostic advantages of
contrast-enhanced MRI mean that it is becoming increasingly important for
patients with a high risk of breast cancer. Women who have already suffered
from breast cancer in the past or who have the so-called 'breast cancer
gene' BRCA-1 or BRCA-2 are regarded as being at high risk.

The multimodality approach in breast cancer diagnostics is particularly
valuable because the different imaging modalities provide medical
professionals with complementary information. In the words of Dr. Carl J.G.
Evertsz, Chairman and CEO of MeVis Medical Solutions AG, 'Our partnership
with Hologic has resulted in the first workstation designed to combine the
latest innovations in digital mammography, breast MRI, digital breast
tomosynthesis, and breast ultrasound. At the same time, we provide medical
professionals with state-of-the-art cross-modality workflow concepts. This
enables them to utilize the wide variety of image data as efficiently and
effectively as possible both in early detection and in diagnostics and
biopsy'.

'This new product generation offers considerable potential for a
fundamental improvement in early detection and diagnosis of breast cancer,'
said Dave Mislan, workstation product manager for Hologic. 'With the
expanded support for all breast imaging modalities, we are ensuring that
patients continue to have access to the best technologies available on the
market in the field of women's health.'

In order to further increase the pace of innovation in the multimodality
approach, the MeVis Group and the Fraunhofer Institute for Medical Image
Computing MEVIS teamed up with leading international partners in the
EU-funded international project HAMAM at the end of 2008. The objective is
to develop a patient-specific diagnostic system for breast cancer that is
universally usable and adaptable.

Images relating to this press release can be found at:
http://www.mevis.de/mms/en/press_material.html

MeVis Medical Solutions AG was founded in 1997 and is one of the world's
leading independent manufacturers and vendors of medical imaging software
with focus on dedicated, disease-oriented clinical applications. Over the
past few years, there has been an enormous increase in the complexity and
volume of medical imaging data derived from digital imaging processes such
as computed tomography (CT), magnetic resonance imaging (MRI), and
ultrasound (US). MeVis Group's products analyze and process this data in
such a way as to provide medical professionals with crucial information for
early detection, diagnosis and intervention in the areas of cancer and lung
diseases as well as neurological conditions. The Group develops its
software solutions in close consultation with the world's leading medical
experts and original equipment makers in the medical technology sector and
primarily markets this software via these partnerships.

27.11.2009 Financial News distributed by DGAP. Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: MeVis Medical Solutions AG
Universitätsallee 29
28359 Bremen
Deutschland
Phone: +49 421 330 74-0
Fax: +49 421 330 74-50
E-mail: ir@mevis.de
Internet: http://www.mevis.de
ISIN: DE000A0LBFE4
WKN: A0LBFE
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, München, Düsseldorf, Stuttgart

End of News DGAP News-Service

---